UNLIMITED TURBO BEAR - NOVO-NORDISK B | Real-time Euronext Paris 16:19:42 04/06/2024 BST | ||
| 0.53 EUR | -14.52% |
|
| Current month | -6.77% | ||
| 1 month | -45.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 04/06/24 | 0.53 | -14.52% |
| 03/06/24 | 0.62 | -6.77% |
| 31/05/24 | 0.665 | +0.76% |
| 30/05/24 | 0.66 | -5.04% |
| 29/05/24 | 0.695 | +3.73% |
Real-time Euronext Paris
Last update June 04, 2024 at 04:19 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| L272S | |
| ISIN | DE000SU2UT22 |
| Date issued | 28/11/2023 |
| Strike | 1,017 kr |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 2.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.535 € |
|---|---|
| Lowest since issue | 0.505 € |
| Spread | 0.02 € |
| Spread % | 3.51% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
923.9
DKK
Average target price
917.3
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- L272S Certificat